Key Points Novo Nordisk needs new products to better compete with Eli Lilly in the weight loss market. Zenagamtide is one of its promising candidates and could, eventually, generate over $1 billion in annual sales. Novo Nordisk's deep pipeline makes it likely to remain a leader in this space over the medium term. 10 stocks we like better than Novo Nordisk › Novo Nordisk 's (NYSE:NVO) semaglutide, sold under the brand names Wegovy and Ozempic, is one of the world's best-selling compounds. Not that this has allowed the company to perform in line with broader equities over the past two years. The pharmaceutical giant has lost a little over 60% of its value over this period. Can Novo Nordisk bounce back?
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.